Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Inclusion Criteria

• •Must have recently completed a course of myeloablative therapy followed by autologous stem cell (bone marrow or peripheral blood) rescue (ASCT)
• •Patients must have a diagnosis of neuroblastoma based upon tumor histology or bone marrow metastases and elevated urine catecholamine metabolites; greater than 98% of neuroblastomas are GD2-positive without intratumor heterogeneity, so these tumors will not be immunostained prior to study entry
• •Patients entered on CCG-3951 may become eligible following the third course of high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue; patients treated on institutional (local) protocols of high-dose chemotherapy with PBSC rescue may also become eligible after one or more courses of PBSC rescue
• •Patients must enter onto study within 8 weeks after the total absolute phagocyte count \[neutrophils (segs + bands) + monocytes\] is \> 1,000/uL; the APC criteria include counts obtained while on G-CSF therapy
• •Patients must have a performance status of 0, 1 or 2 and patients must have a life expectancy of \>= 2 months
• •Serum creatinine =\< 1.5 x normal, or creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 60 ml/min/1.73 m\^2
• •Total bilirubin =\< 1.5 x normal
• •Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 5 x normal
• •Veno-occlusive disease, if present, should be stable or improving
• •Shortening fraction of \>= 27% by echocardiogram, or ejection fraction of \> 50% by gated radionuclide study
• •Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) \> 60% of predicted by pulmonary function test
• •For children who are unable to do pulmonary function tests (PFTs), no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% on room air
• •Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
• •Central nervous system (CNS) toxicity \< grade 2
• •Patients must have a double lumen catheter or single lumen and peripheral IV so that interleukin (IL)-2 and ch14.18 can be given separately